Aripiprazole

Introduction Overview

Generic Name

Aripiprazole

Brand Name

Abilify, Abilify Maintena, Abilify Asimtufii, Aristada, Opipza, Mezofy

Dosage Form

Oral tablet (2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg), oral solution (1 mg/mL), oral film (5 mg, 10 mg, 15 mg), injection (intramuscular), orally disintegrating tablets

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption

Aripiprazole is well absorbed after oral administration with an approximate bioavailability of 87%, exhibiting peak plasma concentrations (Cmax) in about 3 to 5 hours post-dose. Food intake does not significantly affect its absorption, allowing administration with or without meals. The oral solution and oral tablet formulations show similar absorption profiles, while intramuscular injections are designed for slow release maintaining steady plasma concentrations over extended periods.

Distribution

Aripiprazole is extensively distributed throughout the body, exhibiting a large volume of distribution (approximately 4.9 L/kg). It is approximately 99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein. The drug crosses the blood-brain barrier effectively, which is essential for its central nervous system (CNS) activity. In addition, aripiprazole can cross the placenta and is secreted into breast milk, necessitating caution in pregnant and breastfeeding patients.

Metabolism

Aripiprazole undergoes extensive hepatic metabolism primarily through the cytochrome P450 enzymes CYP3A4 and CYP2D6. The primary metabolic pathways include dehydrogenation, hydroxylation, and N-dealkylation, leading to the formation of an active metabolite, dehydro-aripiprazole, which contributes significantly to the drug's therapeutic effects. Genetic polymorphisms in CYP2D6 can affect plasma levels and clinical response. Aripiprazole shows minimal metabolism via other routes.

Elimination

The elimination half-life of aripiprazole is approximately 75 hours, and for its active metabolite around 94 hours, supporting once-daily dosing. The drug and its metabolites are excreted primarily via urine (~27%) and feces (~60%), mostly as metabolites. Due to its long half-life and hepatic metabolism, dosage adjustments may be required in patients with impaired liver function or poor CYP2D6 metabolisms.

Dosage Forms

Adults

Available dosage forms for adults include oral tablets (2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg), oral solution (1 mg/mL), oral films (5 mg, 10 mg, 15 mg), orally disintegrating tablets, and intramuscular injections (Abilify Maintena, Abilify Asimtufii, Aristada). Oral tablets are typically initiated at 10-15 mg once daily for schizophrenia or bipolar I disorder, with a maximum dose up to 30 mg daily depending on clinical response. Intramuscular injections are used for maintenance therapy with dosages ranging from 300 mg to 400 mg monthly for schizophrenia or bipolar disorder.

Adolescents

For children and adolescents, dosing varies by indication and formulation. In schizophrenia, doses may start at 2 mg daily and titrate to 10-15 mg daily in patients aged 13 years and above. For bipolar I disorder in children aged 10 and older, similar dosing ranges apply. Oral films and tablets are approved for use in patients as young as 6 years for treating irritability associated with autistic disorder and Tourette’s disorder, with doses tailored per weight and response. Safety and tolerability are carefully monitored.

Special Populations

In elderly patients and those with hepatic or renal impairment, dosage adjustments are recommended due to slower clearance and increased exposure. For CYP2D6 poor metabolizers, dose reduction by approximately 50% is advised to avoid toxicity. The oral solution contains sugar and should be used cautiously in diabetics. In pregnancy and breastfeeding, aripiprazole should be used only if the potential benefits outweigh the risks, with close monitoring for neonatal extrapyramidal symptoms or withdrawal. Intramuscular formulations require careful handling in patients with limited mobility or medical conditions limiting injection use.

Mechanism Of Action

Aripiprazole is a unique atypical antipsychotic with a distinctive mechanism involving partial agonism at dopamine D2 receptors and serotonin 5-HT1A receptors, and antagonism at serotonin 5-HT2A receptors. This dual activity modulates dopaminergic and serotonergic neurotransmission, contributing to its efficacy in schizophrenia, bipolar disorder, and depression. The partial agonism at D2 receptors results in a stabilizing effect on dopamine neurotransmission, reducing both hyperactive dopaminergic activity linked to psychosis and hypoactivity related to negative symptoms and cognitive deficits. Its 5-HT2A antagonism is thought to enhance dopamine release in certain brain regions and alleviate extrapyramidal symptoms common with other antipsychotics.

Additionally, agonism of 5-HT1A receptors contributes to anxiolytic and antidepressant effects, which may explain aripiprazole's role in adjunctive therapy for major depressive disorder. The balanced receptor activity of aripiprazole reduces adverse effects such as sedation, weight gain, and metabolic disturbances that are frequently associated with typical antipsychotics. Mechanistically, this drug modulates intracellular signaling pathways including those involving cyclic AMP and beta-arrestin pathways, altering neuronal activity and plasticity. Clinical trial evidence supports its efficacy and tolerability across a spectrum of psychiatric disorders due to this pharmacological profile.

Compared to other atypical antipsychotics such as risperidone or olanzapine, which are dopamine antagonists, aripiprazole’s partial agonist action reduces risks of prolactin elevation and extrapyramidal side effects. This contributes to improved adherence and better long-term outcomes in treated patients.

Pharmacological Actions

Partial agonist activity at dopamine D2 receptors, stabilizing dopamine neurotransmission
Partial agonist activity at serotonin 5-HT1A receptors, contributing to anxiolytic and antidepressant effects
Antagonist activity at serotonin 5-HT2A receptors, influencing dopamine release and reducing extrapyramidal symptoms
Modulation of multiple neurotransmitter systems affecting mood, cognition, and behavior
Reduction of psychotic symptoms such as hallucinations and delusions
Mood stabilization in bipolar I disorder, particularly for manic and mixed episodes
Adjunctive antidepressant activity when combined with antidepressants in major depressive disorder
Easing irritability symptoms in Tourette’s disorder and autistic disorder
Improvement of cognition and negative symptoms in schizophrenia
Minimal sedation compared to other atypical antipsychotics
Low propensity for prolactin elevation
Modulation of intracellular signaling pathways involved in neuronal plasticity
Reduction in suicidal ideation and behavior in certain patient populations
Possible metabolic neutrality relative to other antipsychotics
Long-acting injectable formulations allow sustained therapeutic plasma levels

Therapeutic Clinical Uses

Treatment of schizophrenia in adults and adolescents aged 13 years and older
Management of acute manic and mixed episodes in bipolar I disorder in adults and children 10 years and above
Adjunctive treatment for major depressive disorder in adults alongside antidepressants
Treatment of irritability associated with autistic disorder in patients aged 6 to 18 years
Management of Tourette's disorder in patients aged 6 years and older
Maintenance treatment of schizophrenia using long-acting injectable formulations
Maintenance monotherapy treatment of bipolar I disorder in adults with injectable forms
Improvement of mood, behavior, and psychotic symptoms in psychiatric disorders
Treatment of agitation associated with various psychotic disorders (off-label)
Reduction of extrapyramidal symptoms due to favorable receptor activity
Use in patients intolerant to other antipsychotics due to improved side effect profile

Side Or Adverse Effects

Blurred vision
Increased salivation or drooling
Muscle stiffness (rigidity) and tremors
Uncontrolled muscle movements including akathisia and restlessness
Weight gain, though less than other atypical antipsychotics
Nausea, vomiting, and constipation
Changes in appetite, increased or decreased
Headache and dizziness
Drowsiness or fatigue
Sleep disturbances including insomnia
Cold-like symptoms such as stuffy nose, sneezing, sore throat
Severe agitation or distress
Twitching or uncontrollable movements of face or limbs (tardive dyskinesia)
Seizures (convulsions)
Mask-like facial expression and speech difficulties
Hyperglycemia and diabetes risk
Low white blood cell counts leading to infection risk
Increased sexual urges or compulsive behaviors such as gambling
Potential for suicidal ideation especially in young patients
Orthostatic hypotension causing dizziness or falls

Precautions

Use caution in patients with a history of cardiovascular disease or stroke
Monitor blood glucose levels regularly due to risk of hyperglycemia
Closely observe for new or worsening suicidal thoughts or behavior, particularly in younger patients
Avoid abrupt discontinuation to prevent withdrawal symptoms
Use with caution in patients with seizure disorders due to increased seizure risk
Monitor for early signs of neuroleptic malignant syndrome
Avoid alcohol consumption to prevent enhanced sedation and CNS depression
Caution in patients with low white blood cell counts or history of neutropenia
Assess metabolic parameters routinely (lipids, weight, glucose)
Consider dose adjustments in hepatic or renal impairment
Monitor motor symptoms indicative of extrapyramidal side effects
Evaluate pregnancy and breastfeeding status; use only if benefits outweigh risks
Advise patients about potential for dizziness and advises against driving until response is known
Inform patients about potential compulsive behaviors and urge reporting changes
Use cautiously in patients with diabetes or at risk for diabetes
Regular clinical monitoring required during long-acting injectable therapy

Warnings

Not approved for dementia-related psychosis in older adults due to increased mortality risk
Sudden changes in mood or behavior may occur, including aggression or suicidal ideation
Risk of neuroleptic malignant syndrome, characterized by severe muscle rigidity, fever, and autonomic instability
Potential for tardive dyskinesia with prolonged use
Risk of orthostatic hypotension leading to falls, especially in the elderly
Avoid abrupt discontinuation to minimize withdrawal symptoms
High blood sugar and diabetes risk with atypical antipsychotics including aripiprazole
Low white blood cell counts that can lead to serious infections
Risk of seizures, particularly in predisposed individuals
May cause dizziness or sedation impairing ability to perform complex tasks
Use with caution in pregnancy; potential neonatal extrapyramidal and withdrawal symptoms
Potential for impulse control disorders including compulsive gambling and hypersexuality
Consider drug interactions that may increase side effect risk or reduce efficacy
Monitor metabolic parameters regularly
Possibility of rare but serious allergic reactions and anaphylaxis

Contraindications

Known hypersensitivity or allergy to aripiprazole or any component of the formulation
Use in older adults with dementia-related psychosis
Concomitant use with other medications that strongly inhibit both CYP3A4 and CYP2D6 without dose adjustment
Patients with a history of neuroleptic malignant syndrome may be at increased risk
Severe hepatic impairment requiring caution or avoidance
Known phenylketonuria (PKU) for orally disintegrating tablets containing phenylalanine
Patients with uncontrolled diabetes or diabetic ketoacidosis until stabilized
Use caution in patients with seizure disorders or history of seizures
Avoid use in conditions with chronic low white blood cell counts unless closely monitored
Contraindicated in patients with hypersensitivity reactions to previous atypical antipsychotics

Drug Interactions

Inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin) increase aripiprazole plasma levels, necessitating dose reduction
Inhibitors of CYP2D6 (e.g., fluoxetine, paroxetine) increase aripiprazole exposure; dose adjustment required
Inducers of CYP3A4 (e.g., carbamazepine, rifampin) lower aripiprazole levels, possibly reducing efficacy
Concomitant use with other CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation and respiratory depression
Use with caution when combined with antihypertensive drugs due to additive hypotensive effects
Interaction with lithium and valproate may increase neurotoxicity or side effect risks
Drugs prolonging QT interval may increase cardiac risks when combined
Potential interactions with insulin or oral hypoglycemics, requiring blood glucose monitoring
Avoid concomitant use with other dopamine antagonists unless clinically justified
Interactions with CYP450 modifiers require careful monitoring of therapeutic response and adverse effects
Alcohol increases CNS depression and should be avoided
May affect plasma levels of warfarin and other anticoagulants requiring monitoring
Concomitant use with serotonergic agents may increase risk of serotonin syndrome
Avoid concurrent use with drugs causing agranulocytosis due to additive hematologic toxicity

Preparations Of The Drug

Aripiprazole oral tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
Oral solution: 1 mg/mL concentration
Oral films (Mezofy): 5 mg, 10 mg, 15 mg
Orally disintegrating tablets available for rapid dissolution
Intramuscular long-acting injectable formulations: Abilify Maintena (monthly), Abilify Asimtufii (every two months), Aristada (longer-acting), Aristada Initio (initiation injection)
Combination products such as Abilify MyCite with ingestible sensor for adherence monitoring
Film formulation designed for ease of administration in patients with swallowing difficulties
Multiple brand names facilitating access and diverse dosing options
Packaging includes dosing syringes for oral solution to ensure accurate dosing
Administration kits for intramuscular injections with pre-filled syringes